Beam Therapeutics

$40.91
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.84 (+2.02%) Today
-$1.56 (-3.67%) As of 12:34 PM UTC after-hours

Why Robinhood?

You can buy or sell BEAM and other stocks, options, and ETFs commission-free!

About BEAM

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA. The listed name for BEAM is Beam Therapeutics Inc. Common Stock.

CEO
John Evans
Employees
118
Headquarters
Cambridge, Massachusetts
Founded
2017
Market Cap
2.41B
Price-Earnings Ratio
Dividend Yield
Average Volume
610.65K
High Today
$42.90
Low Today
$41.40
Open Price
$42.15
Volume
398.24K
52 Week High
$42.90
52 Week Low
$13.00

Collections

BEAM Earnings

-$1.03
-$0.69
-$0.34
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
per share
Actual
-$0.69 per share

You May Also Like